Please note there are several differences in eligibility between the two tracks; applicants should carefully review the eligibility in their preferred track. Please note that the review committee can only approve moving an applicant between tracks if the applicant meets both tracks’ criteria. Applicants who do not meet eligibility criteria will not be reviewed. Questions about applicant eligibility should be directed to researchgrants@lymphoma.org.

Additionally, to account for training delays or furloughs that may have occurred as a result of the COVID-19 pandemic, LRF is temporarily extending the maximum eligibility for each track by one year, the new limits are noted in the section below.

Applicant Eligibility (Clinical Track):

• Applicants must demonstrate a clear interest and commitment to a career in lymphoma clinical research. This commitment to a career focused on lymphoma-related research should be reflected in the applicant’s career development plan and in the letter of support provided by their mentor.
• Applicants for this track must be one of the following, with requirements calculated per the applicant’s status as of March 1, 2024:
• a junior faculty member with an MD or equivalent degree in their first five years holding a faculty position. Eligible titles include, but are not limited to, Instructor, Clinical Instructor, Assistant Professor and Clinical Assistant Professor.
• a clinical fellow who is at least in their second year of one of the following ACGME accredited subspecialty fellowship programs: Hematology/Oncology, Hematology, Medical Oncology, Radiation Oncology, Pediatric Hematology/Oncology, or Hematopathology. Pathology fellows in one-year fellowship programs and applicants from other clinical sub-specialties will be considered based on the application’s description of the relevance of the research and career development plan to lymphoma, please contact researchgrants@lymphoma.org for eligibility review.
• Applicants should not be more than five years beyond completion of their fellowship or more than thirteen years beyond completion of their MD or equivalent degree as of March 1, 2024.
• Applicants must be affiliated with a sponsoring academic or nonprofit research institution in the U.S. or Canada for the duration of the LSRMP award. Citizenship is not required. LSRMP awards are open to applicants from the NIH or other U.S. government entities.
• Applicants should not be participating in another competitively applied for mentorship (such as ASH’s CRTI) during the LSRMP period (March 2024 through October 2026). Applicants who will have completed other mentorship programs prior to March 2024 are welcome.
• Selected applicants are required to attend and participate in all LSRMP programs in their entirety including the 2024 workshop, follow-up programs (Fall 2024 and 2025), and LRF required communication, reporting, and evaluation.
• Fluency in English.
• Studies or proposals that are exclusively laboratory based are not appropriate for the Clinical Track, please see Laboratory/Translational track eligibility below. Proposals must involve clinical observation of human subjects and may include study or development of new diagnostic methods, therapies, and/or outcome measurements directed to patients with lymphoma. Epidemiology projects are included in this track.
• All applicants must have an identified primary mentor at their home institution who is willing and able to provide financial support for the project and demonstrate a commitment to completing the proposal in order to ensure feasibility of the proposal. Associate mentors, who may provide support for additional aspects of the project and be based at other institutions, are welcome but not a requirement.
• LSRMP applications are self-initiated. LRF does not invite applications from selected individuals, institutions, or laboratories.

Applicant Eligibility(Laboratory/Translational Track):

• Applicants must demonstrate a clear interest and commitment to a career in lymphoma research that is primarily outside of the clinical setting. This commitment to a career focused on lymphoma-related research should be reflected in the applicant’s career development plan and in the letter of support provided by their mentor.
• Applicants with translational projects should apply to the Laboratory Track if their Career Development Plan shows clear commitment to pursuing a career that will focus primarily on non-clinical research, including bench, translational, pathology, and/or statistical research. Applicants who intend to pursue a clinical research career should apply to the Clinical Track with an appropriate project (see point 7 in Clinical Eligibility).
• Applicants for this track must be one of the following, with requirements calculated per the applicant’s status as of March 1, 2024:
• A postdoctoral fellow with no more than eight years as a postdoctoral fellow;
• A clinical fellow who is at least in their second year of an appropriate ACGME accredited sub-specialty fellowship programs including: Hematology/Oncology, Hematology, Medical Oncology, Radiation Oncology, Pediatric Hematology/Oncology, or Hematopathology. Pathology fellows in one-year fellowship programs and applicants from other clinical sub-specialties will be considered based on the application’s description of the relevance of the research and career development plan to lymphoma, please contact researchgrants@lymphoma.org for eligibility review.
• An Instructor (MD, PhD, or equivalent) in their first five years with the title Instructor. MD Instructor applicants should not be more than four years beyond completion of their fellowship or more than twelve years beyond completion of their MD or equivalent degree. PhD Instructor applicants should not be more than thirteen years beyond completion of their PhD or equivalent degree;
• An Assistant Professor (MD, PhD, or equivalent), in the first four years with that title. Assistant Professors must be tenure eligible and spend at least 80% of their time in laboratory research work. They must be the sole PI of their laboratory and must provide an institutional letter documenting commitment to the applicant in terms of space and resources (see item 18, page 11 for details).
• Applicants must be affiliated with a sponsoring academic or nonprofit research institution in the U.S. or Canada for the duration of the LSRMP award. Citizenship is not required. LSRMP awards are open to applicants from the NIH or other U.S. government entities.
• Applicants should not be participating in another competitively applied for mentorship (such as EHA-ASH TRTH) during the LSRMP period (March 2024 through October 2026). Applicants who will have completed other mentorship programs prior to March 2024 are welcome.
• Selected applicants are required to attend and participate in all LSRMP programs in their entirety including the 2024 workshop, follow-up programs (Fall 2024 and 2025), and LRF required communication, reporting, and evaluation.
• Fluency in English.
• Studies or proposals that are primarily clinic-based, even if they have a translational or laboratory aspect are not appropriate for the Laboratory/Translational track, please see Clinical Track eligibility above. Proposals must be specific to mature lymphoid neoplasms including CLL, but not acute lymphoblastic leukemia or myeloma, and may include study of genomics, lymphoma biology and molecular mechanisms, experimental therapeutics, biomarkers, and diagnostic methods directed to patients with lymphoma. Projects MUST include use of, or correlation with, human specimens. Epidemiology projects should apply to the Clinical Track.
• All applicants must have an identified primary mentor at their home institution who is willing and able to provide financial support for the project and demonstrate a commitment to completing the proposal in order to ensure feasibility of the proposal. Associate mentors, who may provide support for additional aspects of the project and be based at other institutions, are welcome but not a requirement.
• LSRMP applications are self-initiated. LRF does not invite applications from selected individuals, institutions, or laboratories.

Eligible Countries:

Sponsor Institute/Organizations: The Lymphoma Research Foundation (LRF)

Sponsor Type:

Address: Wall Street Plaza; 88 Pine Street, Suite 2400; New York, NY 10005;United States

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.